Search Results
Feb 12, 2026, 06:30 ET PBF Energy Reports Fourth Quarter and Full Year 2025 Results, Declares Dividend of $0.275 per Share
work at our Martinez refinery, our current planned turnaround schedule for the first half of 2026 is as follows:Torrance - Q1, CHD/HDTMartinez - Q2, HydrocrackerTiming and throughput ranges provided reflect current expectations and are subject to change based
More news about: PBF Energy Inc.
Feb 04, 2026, 09:30 ET Nicklaus Children's Heart Institute Leads the Region with Groundbreaking Techniques for Congenital Heart Disorders
conditions. These cardiovascular procedures offer hope and solutions to the hundreds of infants and their families born with congenital heart defects (CHD), one of the most common defects in newborns.
More news about: Nicklaus Children's Health System
Feb 03, 2026, 12:07 ET Every 100th Heart Forms to Elevate Congenital Heart Disease on the Federal Policy Agenda
far too long, the CHD community has felt it is underrepresented and underfunded in federal policymaking. CHD drives more than $6 billion in annual hospital costs, and pediatric heart conditions account for an estimated 15% of all pediatric hospital charges nationally — despite CHD patients representing
More news about: Every 100th Heart
Jan 30, 2026, 08:55 ET NYSE Content Advisory: Pre-Market Update + Cast of HBO's 'Industry' Rang Thursday's Closing Bell
Heart Association marks the launch of its "Go Red. Shop with Heart." initiativeClosing BellChurch & Dwight Co., Inc. (CHD) celebrates their 2026 Analyst Day
More news about: New York Stock Exchange
Jan 29, 2026, 17:31 ET Chronic Hepatitis D Market Poised for Significant Growth During the Forecast Period (2025-2034) as Emerging Therapies Drive Optimism | DelveInsight
Chronic Hepatitis D Clinical Trials What is Chronic Hepatitis D?Chronic hepatitis D (CHD) is a severe, progressive liver disease caused by persistent infection with the hepatitis D virus (HDV), a defective RNA virus that can only replicate
More news about: DelveInsight Business Research, LLP
Jan 14, 2026, 09:57 ET 113 Epilepsy Organizations Unite to Express Concerns about Leadership Change at the National Institute of Neurological Disorders and Stroke
Endowment (ARRE) FoundationCACNA1A FoundationCare and Cure InstituteChild Neurology FoundationCoalition to Cure CHD2COMBINEDBrainCSNK2B FoundationCure CLCN6CURE EpilepsyCureGRIN FoundationCureNURR1CureSHANKCURE
More news about: Epilepsy Foundation
Jan 06, 2026, 09:00 ET Mezzion Pharmaceuticals Appoints Physician-Scientist Ridwan Shabsigh, MD, FACS as President & Chief Operating Officer
late-stage rare disease biopharmaceutical company developing the first potential treatment for people born with single ventricle congenital heart disease (SV-CHD) living with Fontan circulation, today announced the appointment of Ridwan Shabsigh, MD, FACS to the newly created role of President and Chief Operating
More news about: Mezzion Pharmaceuticals, Inc
Jan 02, 2026, 17:30 ET PBF Energy Provides Update on Martinez Refinery Operations and Issues 2026 Annual Guidance Information
our refining system. Our current planned turnaround schedule for 2026 is as follows, subject to change:West Coast – Torrance CHD/HDT (Q1), Martinez Hydrocracker (Q2)Gulf Coast – Crude Unit/Coker (Q4)East Coast – Paulsboro Crude Unit (Q4)Mid-continent
More news about: PBF Energy Inc.
Dec 17, 2025, 15:43 ET Norgine enrichit son portefeuille d'hépatologie et de spécialités grâce à un accord de licence exclusif avec Vir Biotechnology
d'elebsiran pour le traitement de l'hépatite D chronique (CHD) en Europe, en Australie et en Nouvelle-Zélande après avoir obtenu les autorisations de commercialisation nécessaires. Les besoins médicaux non satisfaits en matière de traitements efficaces pour la CHD sont importants, compte tenu des limites potentielles
More news about: Norgine Pharmaceuticals Limited
Dec 17, 2025, 07:52 ET Norgine mejora su cartera de productos de hepatología y especialidades
elebsirán para el tratamiento de la hepatitis delta crónica (CHD) en Europa, Australia y Nueva Zelanda, tras obtener las autorizaciones de comercialización necesarias. Existe una gran necesidad médica no cubierta de tratamientos eficaces para la CHD, dadas las posibles limitaciones de las opciones terapéuticas
More news about: Norgine Pharmaceuticals Limited
Dec 17, 2025, 05:30 ET Norgine potenzia il portafoglio di prodotti epatologici e speciali attraverso un accordo di licenza esclusivo concluso con Vir Biotechnology
elebsiran per il trattamento dell'epatite cronica delta (CHD) in Europa, Australia e Nuova Zelanda, dopo aver ottenuto le necessarie autorizzazioni all'immissione in commercio. Esiste una notevole esigenza medica insoddisfatta di trattamenti efficaci per la CHD, dati i potenziali limiti delle opzioni terapeutiche
More news about: Norgine Pharmaceuticals Limited
Dec 17, 2025, 05:23 ET Norgine erweitert sein Hepatologie- und Spezialitätenportfolio durch exklusive Einlizenzierungsvereinbarung mit Vir Biotechnology
chronischer Hepatitis delta (CHD) in Europa, Australien und Neuseeland vermarkten wird, nachdem die erforderlichen Zulassungen erteilt wurden. Angesichts möglicher Einschränkungen bestehender Therapieoptionen besteht ein hoher ungedeckter medizinischer Bedarf an wirksamen Behandlungen für CHD
More news about: Norgine Pharmaceuticals Limited
Dec 17, 2025, 03:01 ET Norgine enhances hepatology and specialty portfolio through exclusive in-licensing agreement with Vir Biotechnology
tobevibart and elebsiran for the treatment of chronic hepatitis delta (CHD) in Europe, Australia and New Zealand following the necessary marketing authorisations. There is a high unmet medical need for effective treatments for CHD given potential limitations with existing treatment options.
More news about: Norgine Pharmaceuticals Limited
Dec 17, 2025, 03:01 ET Norgine enhances hepatology and specialty portfolio through exclusive in-licensing agreement with Vir Biotechnology
tobevibart and elebsiran for the treatment of chronic hepatitis delta (CHD) in Europe, Australia and New Zealand following the necessary marketing authorisations. There is a high unmet medical need for effective treatments for CHD given potential limitations with existing treatment options.
More news about: Norgine Pharmaceuticals Limited
Dec 10, 2025, 12:50 ET Buchanan Capital Partners Forms New Joint Venture with the Industrial Team at Crow Holdings Development
DevelopmentCrow Holdings Development (CHD) is a leading real estate development company specializing in multifamily, industrial, and office development across high-opportunity markets in the United States. Led by a highly experienced leadership team, CHD has developed more than 292,000 multifamily
More news about: Buchanan Capital Partners
Dec 03, 2025, 09:00 ET Mezzion Announces U.S. Patent Allowance Strengthening Udenafil Exclusivity in Fontan Patients
rare disease biopharmaceutical company developing the first treatment specifically for people born with single ventricle congenital heart disease (SV-CHD) who are living with Fontan circulation, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance
More news about: Mezzion Pharmaceuticals, Inc
Nov 19, 2025, 07:12 ET PAN GLOBAL OBTIENT 1,14 G/T D'OR SUR 26 METRES PRÈS DE LA SURFACE SUR LA CIBLE CANADA HONDA DU PROJET ESCACENA, DANS LE SUD DE L'ESPAGNE
l'existence d'une large zone de minéralisation aurifère proche de la surface, qui s'étend sur 150 m en amont-pendage du trou de forage le plus proche (CHD10) et sur 450 m en aval-pendage (ouverte en profondeur et le long de l'axe). Les forages réalisés à ce jour ont recoupé une
More news about: Pan Global Resources Inc.
Nov 18, 2025, 00:30 ET PAN GLOBAL BEPROBT 1,14 G/T GOLD ÜBER 26 METER NAHE DER OBERFLÄCHE IM ZIELGEBIET CANADA HONDA, ESCACENA-PROJEKT, SÜDSPANIEN
Ergebnisse bestätigen eine breite Zone mit einer oberflächennahen Goldmineralisierung, die sich 150 m neigungsaufwärts vom nächsten Bohrloch (CHD10) und 450 m neigungsabwärts erstreckt (in der Tiefe und entlang des Streichens offen). Die bisherigen Bohrungen durchschnitten
More news about: Pan Global Resources Inc.
Nov 18, 2025, 00:30 ET PAN GLOBAL SAMPLES 1.14 G/T GOLD OVER 26 METERS FROM NEAR SURFACE AT CANADA HONDA TARGET, ESCACENA PROJECT, SOUTHERN SPAIN
The results confirm a wide zone of near-surface gold mineralization, extending 150m up-dip from the nearest drillhole (CHD10) and 450m dip-extent (open at depth and along-strike). Drilling to-date intersected copper-gold volcanogenic massive sulphide
More news about: Pan Global Resources Inc.
Nov 18, 2025, 00:30 ET PAN GLOBAL SAMPLES 1.14 G/T GOLD OVER 26 METERS FROM NEAR SURFACE AT CANADA HONDA TARGET, ESCACENA PROJECT, SOUTHERN SPAIN
The results confirm a wide zone of near-surface gold mineralization, extending 150m up-dip from the nearest drillhole (CHD10) and 450m dip-extent (open at depth and along-strike). Drilling to-date intersected copper-gold volcanogenic massive sulphide
More news about: Pan Global Resources Inc.
Nov 18, 2025, 00:30 ET PAN GLOBAL MUESTREA 26 METROS CON 1,14 G/T DE ORO CERCA DE LA SUPERFICIE EN EL OBJETIVO DE CAÑADA HONDA
resultados confirman una amplia zona de mineralización aurífera cerca de superficie, que se extiende 150 m up-dip desde el sondeo más cercano (CHD10) y 450 m en profundidad (quedando abierto en dirección y profundidad). Los sondeos realizados hasta la fecha han interceptado
More news about: Pan Global Resources Inc.
Nov 08, 2025, 10:15 ET AMGEN'S REPATHA® CUTS RISK OF FIRST MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 25% IN LANDMARK PHASE 3 VESALIUS-CV TRIAL
revascularization; CHD death, heart attack or revascularization; cardiovascular death, heart attack or ischemic stroke; and CHD death or heart attack. In addition, there were numerical trends for reduced mortality rates in the Repatha arm, including cardiovascular death (21% relative risk reduction), CHD death (11%
More news about: Amgen
Nov 06, 2025, 02:11 ET Kanazawa University research: Protein droplets in the nucleus guard against cancer
Normally, CHD1 condensates act as hubs that guard tumor-suppressor genes. But this protective system can break down. A cancer-associated mutation known as E1321fs deletes part of CHD1's structure that is essential for forming condensates. Without these droplets, CHD1 cannot properly regulate
More news about: Kanazawa University
Nov 04, 2025, 16:01 ET AMGEN REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS
years.The VESALIUS-CV primary endpoints were time to first occurrence of a composite of coronary heart disease (CHD) death, heart attack or ischemic stroke as well as time to first occurrence of a composite of CHD death, heart attack, ischemic stroke or any ischemia-driven arterial revascularization. The results
More news about: Amgen
Nov 03, 2025, 11:58 ET New Study Explores Placental Malperfusion's Impact on Fetal Health and Development in Congenital Heart Disease
development, is associated with an elevated risk of CHD development and adverse outcomes. Fetuses with CHD often have mothers experiencing higher rates of clinical PMP conditions like preeclampsia. Despite current understanding of the link between PMP and CHD, researchers are delving deeper to better understand
More news about: Children's Hospital of Philadelphia